长效注射PrEP的HIV检测策略:系统综述与荟萃分析
该系统综述与荟萃分析评估了快速诊断检测、实验室免疫分析和核酸扩增检测对长效注射暴露前预防临床效用和项目实施的影响。纳入22项研究共8171名用户,发现快速诊断检测与核酸扩增检测的HIV检出率相似,且快速检测成本更低、周转更快。世界卫生组织新指南支持使用快速诊断检测以简化可负担的HIV检测。
要点
- 快速诊断检测与核酸扩增检测的HIV检出率相似,不良事件无差异。
- 快速诊断检测比实验室检测更快(当日出结果)、治疗启动更早(1天对6-9天)、成本更低(4美元对22美元)。
- 所有检测在启动时阴性预测值约100%,继续使用时阳性预测值约55%。
核心结论
- 基于快速诊断检测的策略与实验室策略准确性相当,且更可及、可扩展,可确保检测不成为获取或继续长效注射暴露前预防的障碍。
研究设计与样本
- 系统综述与荟萃分析,检索截至2025年4月8日的数据库,并补充世界卫生组织调查数据。
- 纳入38篇报告代表22项研究(卡博特韦20项,来那卡帕韦2项),覆盖15个国家。
- 多数为观察性队列(13项)或非随机对照研究(7项),总体证据确定性低。
主要发现
- 在四项随机对照试验的8171名长效注射暴露前预防用户中,快速诊断检测与核酸扩增检测的HIV检出率相似(9/8171对14/8171,OR 0.66,95%CI 0.29-1.50,P=0.87),不良事件无差异。
- 快速诊断检测比实验室检测周转更快(当日对最长7天),治疗启动更快(1天对6-9天),成本更低(4美元对22美元)。
- 所有检测在启动时阴性预测值约100%,继续使用时阳性预测值约55%。延迟HIV检测差异小(快速诊断检测11/8171对核酸扩增检测0/8171)。
- 在HPTN 083试验中,核酸扩增检测偶尔出现假阳性(7/2483),导致不必要的暴露前预防暂停或终止。
关键数值与推荐
- 快速诊断检测与核酸扩增检测的HIV检出率相似(OR 0.66,95%CI 0.29-1.50,P=0.87)。
- 快速诊断检测成本4美元,实验室检测22美元;快速诊断检测当日出结果,实验室检测最长7天。
- 所有检测启动时阴性预测值约100%,继续使用时阳性预测值约55%。
临床怎么用
- 在资源受限环境下扩大长效注射暴露前预防时,采用快速诊断检测可简化检测流程、降低成本并提高可及性。
- 快速诊断检测可支持当日治疗启动,减少因检测延迟导致的暴露前预防中断。
- 需注意核酸扩增检测的假阳性风险,避免不必要的暴露前预防暂停。
局限性
- 总体证据确定性低,多数研究为观察性队列或非随机对照研究。
- 对不同检测策略性能准确性的评估可能引入选择偏倚。
- 关于HIV自检用于长效注射暴露前预防实施的数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-acting injectable pre-exposure prophylaxis (LAI-PrEP) is a highly effective biomedical intervention for the prevention of HIV acquisition. There is a strong interest among communities and policymakers for LAI-PrEP scale-up, accelerating the demand for clear guidance on testing approaches that balance accuracy with scalability. Unlike oral pre-exposure prophylaxis, LAI-PrEP may overcome adherence challenges, such as difficulty with frequent clinic visits. However, LAI-PrEP results in prolonged subtherapeutic drug levels after discontinuation, which can increase the risk of drug resistance among those who have an undetected HIV infection. This systematic review evaluates how different HIV testing strategies, including rapid diagnostic tests (RDTs), laboratory-based immunoassays and nucleic acid testing (NAT), affect clinical utility and programme delivery of LAI-PrEP. METHODS AND FINDINGS: We searched databases and retrieved studies up to April 8, 2025, and supplemented findings with data collected through a World Health Organization (WHO) survey among ongoing and completed LAI-PrEP implementation studies. We included publications reporting original or primary data on clinical, diagnostic and resource-use outcomes of HIV testing for LAI-PrEP. Meta-analyses were conducted using random-effects models. Chi-square tests were used to examine differences between related outcomes. Certainty of evidence was determined using the GRADE methodology (Prospero: CRD42024605562). Risk Of Bias In Non-randomised Studies of Interventions, Version 2 (ROBINS-I V2) assessment tool was used to assess bias for non-randomised comparative studies. Of 7,698 records identified, 38 reports representing 22 studies (cabotegravir: 20, lenacapavir: 2) across 15 countries were included. The overall certainty of evidence was low. Most were observational cohorts (n = 13) or non-randomised comparator studies (n = 7). Among 8,171 LAI-PrEP users in four randomised controlled trials, HIV detection rates were similar across strategies (9/8171 (RDT) versus 14/8171 (NAT) (Odds ratio (OR) 0.66 (95% confidence interval: 0.29-1.50; P = 0.87)), with no difference in adverse events. Compared with laboratory-based tests, RDTs enabled faster turnaround (same-day versus up to 7 days), more rapid treatment initiation (1 day versus 6-9 days), and lower test costs (US$4 versus US$22). All tests had similar negative predictive value (~100%) at LAI-PrEP initiation and comparable positive predictive value (~55%) at continuation. There was little difference in delayed HIV detection (11/8171 (RDT) versus 0/8171 (NAT)). In the HPTN 083 trial, NAT use was occasionally associated with false-positive results, leading to unnecessary PrEP holds or discontinuation (7/2483). NAT might have detected HIV before resistance emerged, though no prospective or modelling evidence showed clinical benefit at a population level. There was limited evidence of HIV self-testing for LAI-PrEP delivery. We noted that our assessment of performance accuracy in different testing strategies may introduce selection bias. CONCLUSIONS: RDT-based testing strategies have comparable accuracy to laboratory-based strategies and are more accessible and scalable, which can ensure that testing does not become a barrier to accessing or continuing LAI-PrEP. As countries expand access to LAI-PrEP amid increasingly constrained resources, adoption of new WHO guidance supporting the use of RDTs can enable simpler, more affordable, and user-centred HIV testing approaches.
引用
- Tieosapjaroen W, Williams E, Johnson CC, et al. Rapid diagnostic tests, laboratory-based immunoassay and nucleic acid testing strategies for long-acting injectable pre-exposure prophylaxis: A systematic review and meta-analysis. PLoS Med. 2026. PMID: 41990088. doi:10.1371/journal.pmed.1005030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。